PAR · ALMDT.PA
Median Technologies S.A.
€4.26-€0.12 (-2.63%)
Median Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
Loading market information…
PAR · ALCJ.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Crossject S.A.’s quoted price sits in the lower half of its reported 52-week range, 52.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Crossject S.A.’s next earnings report is currently expected on Mar 31, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Crossject S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Crossject S.A. is dedicated to pioneering needle-free drug delivery solutions. A key innovation from the company is ZENEO, a prefilled, single-use auto-injector that eliminates the need for a traditional needle. Crossject is actively advancing a portfolio of drugs through clinical trials, all intended for administration via its ZENEO system. This pipeline includes Sumatriptan for treating migraines and cluster headaches, Adrenaline for severe allergic reactions (anaphylactic shock), Hydrocortisone for acute adrenal insufficiency, Midazolam for managing epileptic seizures, Naloxone for opioid overdose, Apomorphine for temporary paralysis in Parkinson's patients, Methotrexate for rheumatoid arthritis, and Terbutaline for acute asthma attacks. Founded in 1997, the company maintains its operational base in Dijon, France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| €500.00K-95.43% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€4.26-€0.12 (-2.63%)
Median Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
€1.29+€0.01 (+0.63%)
Innate Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.81% below the high.
€2.81€0.00 (0.0%)
Affluent Medical S.A.’s quoted price sits in the upper half of its reported 52-week range, 4.75% below the high.
€16,100.00€0.00 (0.0%)
Eurofins-Cerep S.A.’s quoted price sits in the lower half of its reported 52-week range, 21.84% below the high.
€1.69+€0.02 (+1.07%)
ABIONYX Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 63.17% below the high.
€3.06-€0.06 (-1.99%)
Adocia S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.29% below the high.
€8.90+€0.10 (+1.14%)
Sensorion S.A.’s quoted price sits in the lower half of its reported 52-week range, 77.97% below the high.
€2.11-€0.08 (-3.84%)
OSE Immunotherapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 65.48% below the high.
